Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics (Q28254233)

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Mutational analysis of the tyrosine kinome in colorectal cancers

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Cdk2 knockout mice are viable

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Mutations of the BRAF gene in human cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Protein misfolding, evolution and disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

A census of human cancer genes

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Guilty as charged: B-RAF is a human oncogene

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

21 April 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Molecular chaperones in the cytosol: from nascent chain to folded protein

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Finishing the euchromatic sequence of the human genome

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

The 'sequential allosteric ring' mechanism in the eukaryotic chaperonin-assisted folding of actin and tubulin

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

The protein kinase complement of the human genome

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Hsp90 as a capacitor for morphological evolution

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Cancer genes and the pathways they control

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Hsp90: a specialized but essential protein-folding tool

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone

21 April 2017

1 reference

https://api.crossref.org/works/10.1101/SQB.2005.70.020

Protein folding in the cell

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Protein kinases--the major drug targets of the twenty-first century?

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Folding of newly translated proteins in vivo: the role of molecular chaperones

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Pathways of chaperone-mediated protein folding in the cytosol

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 April 2017

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The genetics and genomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Hsp90 & Co. - a holding for folding

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Getting newly synthesized proteins into shape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

ATPases as drug targets: learning from their structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Hsp90: the vulnerable chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

PTEN, a unique tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Trigger factor and DnaK cooperate in folding of newly synthesized proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The fundamentals of protein folding: bringing together theory and experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Molecularly targeted therapy: have the floodgates opened?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Role of the heat shock response and molecular chaperones in oncogenesis and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Eukaryotic chaperonin CCT stabilizes actin and tubulin folding intermediates in open quasi-native conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Molecular chaperones and the stress of oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Protein folding: progress made and promises ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Hsp90 as a therapeutic target in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

PI3-kinase inhibition: a target for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Proliferation of cancer cells despite CDK2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

In vivo newly translated polypeptides are sequestered in a protected folding environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

NAC covers ribosome-associated nascent chains thereby forming a protective environment for regions of nascent chains just emerging from the peptidyl transferase center

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Mutational analysis of the tyrosine phosphatome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Therapeutic potential of phosphoinositide 3-kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Hsp70 and Hsp90--a relay team for protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Somatic alterations in the human cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Paul Workman--at the cutting edge of drug discovery (interview by Dorothy Bonn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Challenges of PK/PD measurements in modern drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Paul Workman on the challenges of cancer drug development. Interview by Katharine E. Pestell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Overview: Translating Hsp90 Biology into Hsp90 Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Altered states: selectively drugging the Hsp90 cancer chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Translating basic cancer research into new cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Role of BAX in the apoptotic response to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020

Improving outcomes in advanced malignant melanoma: update on systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.020